Stryker (SYK) Stock Price, News & Analysis

Company Overview

Stryker Corporation is a leading global medical technology company specializing in innovative healthcare solutions. The company develops, manufactures and sells a diverse range of products and services in three primary segments: Orthopedics, MedSurg and Neurotechnology & Spine. Its Orthopedics division offers joint replacement implants, trauma products and reconstructive solutions, while its MedSurg segment provides surgical equipment, endoscopic and communications systems, patient handling and emergency medical equipment. The Neurotechnology & Spine group focuses on devices for the management of neurological and spinal disorders, including implants for spinal fusion, aneurysm treatment and brainshunt procedures.

Founded in 1941 by Dr. Homer Stryker in Kalamazoo, Michigan, the company grew from a small medical device shop into a Fortune 500 enterprise. Throughout its history, Stryker has expanded its product portfolio and geographic footprint through internal research and strategic acquisitions. Key acquisitions have included companies specializing in robotic surgery, wound care and advanced imaging, which have enhanced Stryker’s ability to offer end-to-end surgical solutions and minimally invasive treatment options.

Today, Stryker operates in more than 100 countries with manufacturing facilities, research and development centers and sales offices across North America, Europe, Asia Pacific, Latin America and the Middle East. The company invests heavily in R&D to advance technologies such as surgical robotics, digital operating room integration and personalized orthopedics. Its global supply chain and localized customer support help ensure timely product delivery and training for healthcare professionals.

Under the leadership of President and Chief Executive Officer Kevin A. Lobo, who has guided the company since 2012, Stryker emphasizes a culture of integrity, innovation and customer focus. The executive team maintains a commitment to quality, compliance and continuous improvement, while fostering collaboration with clinicians, researchers and industry partners to address evolving patient needs and drive long-term growth.

Key Stats

• Today's Range: $366.47 to $372.88
• 50-Day Range: $364.07 to $394.67
• 52-Week Range: $329.16 to $406.19
• Volume: 488,073 shs
• Average Volume: 1.41 million shs
• Market Capitalization: $140.27 billion
• P/E Ratio: 48.58
• Dividend Yield: 0.92%
• Price Target: $431.76
• Consensus Rating: Moderate Buy

Stryker Stock Analysis - MarketRank™

Stryker scored higher than 99% of companies evaluated by MarketBeat, and ranked 10th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Stryker has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 15 buy ratings, 6 hold ratings, and no sell ratings.

Upside Potential

Stryker has a consensus price target of $431.76, representing about 17.2% upside from its current price of $368.45.

Amount of Analyst Coverage

Stryker has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.10%

Earnings Growth

Earnings for Stryker are expected to grow by 10.10% in the coming year, from $13.47 to $14.83 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Stryker is 48.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 233.14.

Price to Earnings Ratio vs. Sector

The P/E ratio of Stryker is 48.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.67.

Price to Earnings Growth Ratio

Stryker has a PEG Ratio of 2.67. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Stryker has a P/B Ratio of 6.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.29% of the float of Stryker has been sold short.

Short Interest Ratio / Days to Cover

Stryker has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Stryker has recently increased by 10.02%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Stryker has a dividend yield of 0.92%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Stryker has been increasing its dividend for 32 years.

Dividend Coverage

The dividend payout ratio of Stryker is 44.50%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Stryker will have a dividend payout ratio of 22.66% next year. This indicates that Stryker will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.95

Percentage of Shares Shorted

1.29% of the float of Stryker has been sold short.

Short Interest Ratio / Days to Cover

Stryker has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Stryker has recently increased by 10.02%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.41

News Sentiment

Stryker has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 44 news articles for Stryker this week, compared to 40 articles on an average week.

Search Interest

39 people have searched for SYK on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.

MarketBeat Follows

18 people have added Stryker to their MarketBeat watchlist in the last 30 days. This is an increase of 260% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Stryker insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $75,485,305.00 in company stock.

Percentage Held by Insiders

Only 5.90% of the stock of Stryker is held by insiders.

Percentage Held by Institutions

77.09% of the stock of Stryker is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SYK Stock Analysis - Frequently Asked Questions

How have SYK shares performed this year?

Stryker's stock was trading at $360.05 at the start of the year. Since then, SYK shares have increased by 2.3% and is now trading at $368.45.

How were Stryker's earnings last quarter?

Stryker Corporation (NYSE:SYK) announced its quarterly earnings results on Thursday, July, 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. The business's quarterly revenue was up 11.1% compared to the same quarter last year.
Read the conference call transcript.

Does Stryker have any subsidiaries?

Stryker subsidiaries include these companies: Vocera Communications, Vocera, Gauss Surgical, OrthoSensor, Wright Medical Group, Cardan Robotics, Mobius Imaging, and more.

Who are Stryker's major shareholders?

Top institutional investors of Stryker include Voya Investment Management LLC (0.13%), CCLA Investment Management (0.10%), Confluence Investment Management LLC (0.06%) and Chesley Taft & Associates LLC (0.04%). Insiders that own company stock include Ronda E Stryker, Kevin Lobo, James Andrew Pierce, Allan C Golston, Viju Menon, M Kathryn Fink, Robert S Fletcher, Srikant M Datar, William E Berry Jr and Glenn S Boehnlein.
View institutional ownership trends.

How do I buy shares of Stryker?

Shares of SYK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Stryker own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Stryker investors own include Broadcom (AVGO), ServiceNow (NOW), BlackRock (BLK), NVIDIA (NVDA), Meta Platforms (META), UnitedHealth Group (UNH) and Advanced Micro Devices (AMD).

Company Calendar

• Record date for 7/31 Dividend: 6/30/2025
• Ex-Dividend for 7/31 Dividend: 6/30/2025
• Last Earnings: 7/31/2025
• Dividend Payable: 7/31/2025
• Record date for 10/31 Dividend: 9/30/2025
• Ex-Dividend for 10/31 Dividend: 9/30/2025
• Today: 10/16/2025
• Next Earnings (Estimated): 10/30/2025
• Dividend Payable: 10/31/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:SYK
• CIK: 310764
• Web: www.strykercorp.com
• Phone: (269) 385-2600
• Fax: 269-385-1062
• Employees: 53,000
• Year Founded: 1941

Price Target and Rating

• Average Price Target for Stryker: $431.76
• High Price Target: $456.00
• Low Price Target: $405.00
• Potential Upside/Downside: +16.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.55
• Trailing P/E Ratio: 48.95
• Forward P/E Ratio: 27.44
• P/E Growth: 2.67
• Net Income: $2.99 billion
• Net Margins: 12.25%
• Pretax Margin: 14.07%
• Return on Equity: 23.94%
• Return on Assets: 11.08%

Debt

• Debt-to-Equity Ratio: 0.70
• Current Ratio: 1.78
• Quick Ratio: 1.06

Sales & Book Value

• Annual Sales: $23.82 billion
• Price / Sales: 5.93
• Cash Flow: $15.07 per share
• Price / Cash Flow: 24.53
• Book Value: $54.13 per share
• Price / Book: 6.83

Miscellaneous

• Outstanding Shares: 382,307,000
• Free Float: 359,751,000
• Market Cap: $141.30 billion
• Optionable: Optionable
• Beta: 0.94